- AI
- Arbitration
- Asia
- Automobile
- Bangladesh
- Banking
- Biodiversity
- Biological Inventions
- bLAWgathon
- Brand Valuation
- Business
- Celebrity Rights
- Company Act
- Company Law
- Competition Law
- Constitutional Law
- Consumer Law
- Consumer Protection Authority
- Copyright
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Counterfeiting
- Covid
- Design
- Digital Media
- Digital Right Management
- Dispute
- Educational Conferences/ Seminar
- Environment Law Practice
- ESIC Act
- EX-Parte
- Farmer Right
- Fashion Law
- FDI
- FERs
- Foreign Law
- Gaming Industry
- GDPR
- Geographical Indication (GI)
- GIg Economy
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- IBC
- India
- Indonesia
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- IT Act
- IVF technique
- Judiciary
- Khadi Industries
- labour Law
- Legal Case
- Legal Issues
- Lex Causae
- Licensing
- Live-in relationships
- Lok Sabha Bill
- Marriage Act
- Maternity Benefit Act
- Media & Entertainment Law
- Mediation Act
- Member of Parliament
- Mergers & Acquisition
- Myanmar
- NCLT
- NEPAL
- News & Updates
- Non-Disclosure Agreement
- Online Gaming
- Patent Act
- Patent Commercialisation
- Patent Fess
- Patent Filing
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent Rule Amendment
- Patents
- pharma
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Pollution
- Posh Act
- Protection of SMEs
- RERA
- Section 3(D)
- Signapore
- Social Media
- Sports Law
- Stamp Duty
- Stock Exchange
- Surrogacy in India
- TAX
- Technology
- Telecom Law
- Telecommunications
- Thailand
- Trademark
- Trademark Infringement
- Trademark Litigation
- Traditional Knowledge
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
THE TRADE MARK RULES, 2017: AT A GLANCE Simple. Straightforward. Faster.
The Trade Mark Rules, 2017 notified and came into effect on 6th March 2017 repealing the Trade Mark Rules, 2002. These rules have been framed with the intention of simplifying and expediting the procedure for registration of Trade Marks in India. Key Highlights of the New Rules: Categorization of Applicant and Fees Increase in Fees … Continue reading THE TRADE MARK RULES, 2017: AT A GLANCE Simple. Straightforward. Faster.
Read more »BLACKBERRY SUES NOKIA FOR PATENT INFRINGEMENT: AN OVERVIEW
The once-powerful mobile phone companies BlackBerry and Nokia are in the headlines again, not for their new technological developments but because of their legal battle. The Valentine’s Day card for Nokia was in the form of a complaint entailing 11 items that Blackberry did not like about it. The complaint listed out the 11 patents … Continue reading BLACKBERRY SUES NOKIA FOR PATENT INFRINGEMENT: AN OVERVIEW
Read more »FRAND-ING PATENT LICENSES AND ITS IMPLICATION IN LANDMARK CASES IN INDIA
Everyday, a number of products are being invented all over the world, some cascading over the improvement of existing inventions, and the others, portraying a unique set of methods and products unknown to man at large. Simultaneously, there is an eruption of infringements that remain unnoticed or noticed following an incredulous load of proceedings and … Continue reading FRAND-ING PATENT LICENSES AND ITS IMPLICATION IN LANDMARK CASES IN INDIA
Read more »Expedited examination and non-expedited (normal) examination: Who can file request for examination?
With effect from May 16, 2016 (effective date for Patent (amendment) rules, 2016), provision of expedited examination was introduced in the Patent system of India. This article does not intend to discuss the different timelines within which request for examination has to be filed in different situations, rather article is restricted to the eligibility of … Continue reading Expedited examination and non-expedited (normal) examination: Who can file request for examination?
Read more »Teva held responsible for Induced Infringement of Eli Lilly’s Blockbuster drug ALITMA
In Teva Parenteral Medicines, Inc.; APP Pharmaceuticals LLC; Pliva Hrvatska D.O.O.; Teva Pharmaceuticals USA, Inc.; and Barr Laboratories, Inc. (hereinafter referred to be as Defendants/Appellants/Teva) Vs. Eli Lilly & Co. (hereinafter referred to as Plaintiff/Appelle/Eli Lilly) decided by United States Court of Appeals for the Federal Circuit (CAFC) on January 12, 2017, Plaintiff had filed … Continue reading Teva held responsible for Induced Infringement of Eli Lilly’s Blockbuster drug ALITMA
Read more »Obtaining a Certificate of Recognition from DIPP for IPR benefits
“A start-up would now require only a certificate of recognition from the Department of Industrial Policy and Promotion (DIPP) and would not be required to be examined by the inter-ministerial board, as was being done earlier. This is one rapid change that we have brought in,” said Nirmala Sitharaman, Minister of Commerce and Industry in … Continue reading Obtaining a Certificate of Recognition from DIPP for IPR benefits
Read more »Effect of Union Budget, 2017 on the R&D/ Intellectual Property Practices in India
Union budget that was highly waited for (after demonetization) had gained more attention also due to preponing to February 01, 2017. As a matter of fact, every year budget has certain impact on various industries including IP industry and R&D sectors. In this article, we will try to analyze possible effects of 2017 budget on … Continue reading Effect of Union Budget, 2017 on the R&D/ Intellectual Property Practices in India
Read more »India: Do we need Patent Term Extension and Non-Patent Exclusivities for Pharmaceuticals?
India, though in a phase of rapid economic development, still has the bane of poverty. In this country, around 22% of the population is Below the Poverty Line [1], and hence most of the nation’s policies are oriented towards the poor. India’s IP Policy is no different, as the IP legislature in India is mostly … Continue reading India: Do we need Patent Term Extension and Non-Patent Exclusivities for Pharmaceuticals?
Read more »First Symposium of IIPRD in 2017
After successfully conducting several symposiums in 2016, IIPRD is coming up with one-day seminar on software and electronics patent portfolio with focus on preliminary preparation, prosecution, and litigation in India and US. While the programme is being organized in Pune on February 23, the one in Bengaluru will be hosted February 24. The seminar is … Continue reading First Symposium of IIPRD in 2017
Read more »Analysis of the rejection of Lumacaftor (Polymorph) patent application in India
We have been receiving requests from our Pharma clients/readers of the blog for the analysis of the decision/ facts that led to rejection of Lumacaftor (Polymorph) patent application in India since last year. Here is our take: Details of the Patent Application and important dates: Patent application number in India 2056/KOLNP/2010 Title of the invention … Continue reading Analysis of the rejection of Lumacaftor (Polymorph) patent application in India
Read more »